ABT-869
Dual VEGFR and PDGFR kinase inhibitor / ABT-869 (796967-16-3) ia a structurally novel, potent inhibitor of receptor tyrosine kinases inhibiting VEGFR and PDGFR and related kinases with IC50s= 3, 4, 4, 66, 3 and 14 nM for VEGFR1, VEGFR2, FLT3, PDGFRβ, CSF-1R and KIT respectively.1,2 Protects cells from necroptosis and rescues SIRS mice from TNF-α-induced shock and death.3 Exerts anti-obesity effects by promoting adipocyte browning.4 Inhibits angiogenesis.5
Biochemicals & reagents
796967-16-3
Linifanib
1 Albert et al. (2006), Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor; Cancer Ther., 5 995 2 Guo et al. (2006), Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors; Cancer Ther., 5 1007 3 Yu et al. (2023), Repositioning linifanib as a potent anti-necroptosis agent for sepsis; Cell Death Discov., 9 57 4 Zhao et al. (2019), Linifanib exerts dual anti-obesity effect by regulating adipocyte browning and formation; Life Sci., 222 117 5 Raoul et al. (2017), An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma; Expert Opin. Pharmacother., 18 1467
-20°C
TARGET: Kinase -- PATHWAY: AKT; mTOR; Necroptosis -- RESEARCH AREA: Cell death; Angiogenesis -- DISEASE AREA: Cancer; Obesity